According to media reports, Swedish biotech giant Camurus AB is rumored to be in talks to acquire US-based Braeburn Pharmaceuticals, a move that could deepen its foothold in the world’s largest market for opioid addiction treatments.
While financial details remain undisclosed, the acquisition would mark a major step for the Lund-based company, which specializes in long-acting treatments for chronic and severe conditions, including substance use disorders.
Camurus and Braeburn have been partners for over a decade. In 2014 Camurus granted Braeburn exclusive rights to commercialize its long-acting buprenorphine injection — marketed as Brixadi in the US and Buvidal eslewhere. The licensing deal brought Camurus $20 million upfront and up to $151 million in milestone payments tied to development and sales.
Brixadi, approved by the US Food and Drug Administration in late 2023, quickly gained traction among physicians and patients. Braeburn has leveraged its distribution network across Medicaid, Medicare, federal and commercial payers to accelerate uptake.
By the end of 2024 Brixadi captured roughly a quarter of the US market for long-acting buprenorphine, significantly surpassing previous launches in this segment and generating over $19 million in royalty income for Camurus. It is well-positioned as a leading competitor due to its weekly and monthly formulations and ease of administration compared to daily therapies.
The US opioid treatment market is projected to expand as federal initiatives increase access to medications that curb cravings and withdrawal, according to Hagman Global Strategies, a London-based think tank. Analysts estimate the US market potential for Brixadi at more than $1 billion, driven by strong uptake among prescribers, patients and payers.
The US remains at the epicenter of the opioid epidemic, where synthetic opioids like fentanyl contribute to nearly 80,000 overdose deaths annually. Demand for effective treatment options continues to grow as federal initiatives expand access to medication-assisted therapies.
For Camurus, acquiring Braeburn would mean taking direct control of Brixadi’s US commercialization — and securing a stronger position in its most critical growth market.
